 |
|
Cost-effectiveness of B-Type Natriuretic Peptide Testing in Patients With Acute Dyspnea
Christian Mueller, MD;
Kirsten Laule-Kilian, BSc;
Christian Schindler, PhD;
Theresia Klima, MD;
Barbara Frana, MD;
Daniel Rodriguez, MD;
André Scholer, PhD;
Michael Christ, MD;
André P. Perruchoud, MD
Arch Intern Med. 2006;166:1081-1087.
Background B-type natriuretic peptide (BNP) is a quantitative marker of heart failure that seems to be helpful in its diagnosis.
Methods We performed a prospective randomized study (B-Type Natriuretic Peptide for Acute Shortness of Breath Evaluation) including 452 patients who presented to the emergency department with acute dyspnea to estimate the long-term cost-effectiveness of BNP guidance. Participants were randomly assigned to a diagnostic strategy involving the measurement of BNP levels (n = 225) or assessment in a standard manner (n = 227). Nonparametric bootstrapping was used to estimate the distribution of incremental costs and effects on the cost-effectiveness plane during 180 days of follow-up.
Results Testing of BNP induced several important changes in management of dyspnea, including a reduction in the initial hospital admission rate, the use of intensive care, and total days in the hospital at 180 days (median, 10 days [interquartile range, 2-24 days] in the BNP group vs 14 days [interquartile range, 6-27 days] in the control group; P = .005). At 180 days, all-cause mortality was 20% in the BNP group and 23% in the control group (P = .42). Total treatment cost was significantly reduced in the BNP group ($7930 vs $10 503 in the control group; P = .004). Analysis of incremental 180-day cost-effectiveness showed that BNP guidance resulted in lower mortality and lower cost in 80.6%, in higher mortality and lower cost in 19.3%, and in higher or lower mortality and higher cost in less than 0.1% each. Results were robust to changes in most variables but sensitive to changes in rehospitalization with BNP guidance.
Conclusion Testing of BNP is cost-effective in patients with acute dyspnea.
Author Affiliations: Department of Internal Medicine (Drs Mueller, Klima, Frana, Rodriguez, Christ, and Perruchoud and Ms Laule-Kilian), Institute of Social and Preventive Medicine (Dr Schindler), and Department of Laboratory Medicine (Dr Scholer), University Hospital, University of Basel, Basel, Switzerland.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Utility of B-Type Natriuretic Peptide Testing in the Emergency Department
Giorgio Costantino, Anna Maria Rusconi, Giovanni Casazza, and Nicola Montano
Arch Intern Med. 2006;166(20):2287.
EXTRACT
| FULL TEXT
Utility of B-Type Natriuretic Peptide Testing in the Emergency Department—Reply
Christian Mueller, Kirsten Laule-Kilian, Michael Christ, and André P. Perruchoud
Arch Intern Med. 2006;166(20):2288.
EXTRACT
| FULL TEXT
RELATED ARTICLES
The Value of BNP Testing
Mark Hlatky and Paul Heidenreich
Arch Intern Med. 2006;166(10):1063-1064.
EXTRACT
| FULL TEXT
Accuracy of B-Type Natriuretic Peptide Tests to Exclude Congestive Heart Failure: Systematic Review of Test Accuracy Studies
Markus Battaglia, Daniel Pewsner, Peter Jüni, Matthias Egger, Heiner C. Bucher, and Lucas M. Bachmann
Arch Intern Med. 2006;166(10):1073-1080.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
State of the art: Using natriuretic peptide levels in clinical practice
Maisel et al.
Eur J Heart Fail 2008;10:824-839.
ABSTRACT
| FULL TEXT
Clinical Uncertainty, Diagnostic Accuracy, and Outcomes in Emergency Department Patients Presenting With Dyspnea
Green et al.
Arch Intern Med 2008;168:741-748.
ABSTRACT
| FULL TEXT
Discriminating Between Cardiac and Pulmonary Dysfunction in the General Population With Dyspnea by Plasma Pro-B-Type Natriuretic Peptide
Mogelvang et al.
J Am Coll Cardiol 2007;50:1694-1701.
ABSTRACT
| FULL TEXT
Medical and Economic Long-term Effects of B-Type Natriuretic Peptide Testing in Patients with Acute Dyspnea
Breidthardt et al.
Clin. Chem. 2007;53:1415-1422.
ABSTRACT
| FULL TEXT
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure
Wilson Tang et al.
Circulation 2007;116:e99-e109.
FULL TEXT
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2007;28:1598-1660.
FULL TEXT
Can We IMPROVE-CHF Management By Measuring Natriuretic Peptides?
Greenberg
Circulation 2007;115:3045-3047.
FULL TEXT
N-Terminal Pro-B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study
Moe et al.
Circulation 2007;115:3103-3110.
ABSTRACT
| FULL TEXT
B type natriuretic peptide testing was more cost effective than conventional diagnosis in patients with acute dyspnoea
Shetty and Garber
Evid. Based Med. 2007;12:28-28.
FULL TEXT
Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty
Cleland et al.
Eur J Heart Fail 2007;9:92-97.
ABSTRACT
| FULL TEXT
Utility of B-Type Natriuretic Peptide Testing in the Emergency Department--Reply
Mueller et al.
Arch Intern Med 2006;166:2288-2288.
FULL TEXT
Utility of B-type natriuretic Peptide testing in the emergency department.
Costantino et al.
Arch Intern Med 2006;166:2287-2287.
FULL TEXT
BNP Testing: A Mixed Blessing
JWatch Emergency Med. 2006;2006:4-4.
FULL TEXT
BNP Testing for Acute Dyspnea: Is It Cost-Effective?
Journal Watch Cardiology 2006;2006:6-6.
FULL TEXT
The Value of BNP Testing.
Hlatky and Heidenreich
Arch Intern Med 2006;166:1063-1064.
FULL TEXT
|
